Entrada Therapeutics, Inc.
TRDA
$11.88
-$0.71-5.64%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
3/18/2026
-
Tickeron - Technical Analysis
3/17/2026
-
Tickeron - Technical Analysis
3/14/2026
-
Tickeron - Technical Analysis
3/13/2026
-
Tickeron - Technical Analysis
3/12/2026
-
MarketBeat
3/12/2026
-
Tickeron - Stocks
3/11/2026
-
Ticker Report
3/11/2026
-
MarketBeat
3/11/2026
-
MarketBeat
3/11/2026
-
MarketBeat
3/11/2026
-
MarketBeat
3/11/2026
-
Tickeron - Stocks
3/10/2026
-
MarketBeat
3/10/2026
-
Tickeron - Technical Analysis
3/7/2026
-
MarketBeat
3/7/2026
-
Tickeron - Technical Analysis
3/6/2026
-
MarketBeat
3/6/2026
-
MarketBeat
3/2/2026
-
Globe Newswire
2/28/2026
-
Tickeron - Technical Analysis
2/28/2026
-
MarketBeat
2/27/2026
-
Tickeron - Stocks
2/27/2026
-
Simply Wall St
2/26/2026
-
TipRanks Financial Blog
2/26/2026
-
MarketBeat
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, February 26, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 4 and 8 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
857 520 9158
Address
One Design Center Place
Boston, MA 02210
Boston, MA 02210
Country
Year Founded
Business Description
Sector
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that...
more